HX008

DRUG11 trials

Conditions

Advanced Solid TumorAnaplastic Thyroid CancerBladder CancerHepatocellular CarcinomaMelanomaMetastatic Colorectal CancerNonsquamous Non-small Cell Lung CancerPenile Cancer

Phase 1

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

NCT04756934

Taizhou HoudeAoke Biomedical Co., Ltd.Melanoma

Start: 2020-08-20End: 2022-08-20Target: 63Updated: 2021-02-16

A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

NCT04825392

Taizhou Hanzhong biomedical co. LTDAdvanced Solid Tumor

Start: 2019-09-05End: 2021-12-30Target: 30Updated: 2021-04-01

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

Not yet recruitingNCT07054307

Jiyan LiuPenile Cancer

Start: 2025-07-30End: 2030-07-30Target: 10Updated: 2025-07-08

Phase 2

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

NCT04574817

Taizhou Hanzhong biomedical co. LTDAnaplastic Thyroid Cancer

Start: 2020-12-28End: 2023-05-30Target: 66Updated: 2020-10-05

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04738630

Taizhou Hanzhong biomedical co. LTDBladder Cancer

Start: 2020-09-25End: 2023-12-01Target: 110Updated: 2021-02-04

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

NCT04741165

Taizhou Hanzhong biomedical co. LTDHepatocellular Carcinoma

Start: 2021-01-07End: 2022-10-30Target: 72Updated: 2021-02-05

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

NCT04749485

Taizhou Hanzhong biomedical co. LTDMelanoma

Start: 2018-11-08End: 2021-11-08Updated: 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

NCT04750083

Taizhou Hanzhong biomedical co. LTDNonsquamous Non-small Cell Lung Cancer

Start: 2020-09-25End: 2023-09-25Target: 700Updated: 2021-02-11

Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN).

RecruitingCTIS2023-510558-18-00

Groupe Oncologie Radiotherapie Tete Coulocally advanced head and neck squamous cell carcinoma

Start: 2025-10-13Target: 106Updated: 2025-06-24

Phase 3

HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

NCT04486651

Taizhou Hanzhong biomedical co. LTDStomach Cancer

Start: 2020-09-16End: 2023-08-10Target: 560Updated: 2021-01-28

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruitingNCT05652894

Taizhou Hanzhong biomedical co. LTDMetastatic Colorectal Cancer

Start: 2022-12-20End: 2028-10-20Target: 190Updated: 2022-12-15

Related Papers

Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).

Journal of Clinical Oncology2023-06-01

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.

2023-02-0614 citations

Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma—A single-arm, multicenter, phase II study.

Journal of Clinical Oncology2021-05-204 citations